Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California and currently employs 34 full-time employees. The firm is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The firm in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The firm has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.